Project Grant R21DA067366
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $427K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Richmond, VA 23298, USA
Similar Awards
- The National Institute on Drug Abuse awarded the University of Pittsburgh $701,569 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research on the use and effectiveness of medications for opioid use disorder in older adults with multimorbidity. The award funds quantitative studies of Medicare and Veterans Health Administration enrollees with diagnosed opioid use disorder and a qualitative study of older adults with opioid use disorder and...
- The National Institute on Drug Abuse (NIDA) awarded a Cooperative Agreement of $733,457 to The Washington University on May 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279). The award funds research investigating the long-term neurodevelopmental impact of maternal opioid exposure and opioid management strategies in rodent offspring. The project evaluates how in utero oxycodone exposure, maintenance therapy with methadone and buprenorphine, and withdrawal mitigation...
- The National Institute on Drug Abuse awarded Yale University $641,138 on June 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a study examining methadone dose-associated risks and outcomes in opioid use disorder treatment, with particular focus on aging adults. The research leverages a national cohort of approximately 54,000 patients receiving care in the Department of Veterans Affairs, derived from the Veterans Aging Cohorts Study's national cohort...
- The National Institute on Drug Abuse awarded the University of Maryland, Baltimore $1,371,874 under the Drug Use and Addiction Research Programs (CFDA 93.279) on March 15, 2026, to investigate the impact of opioid use disorder on mitochondrial dysfunction among antiretroviral therapy-receiving aging people with HIV. The research addresses a gap in understanding how long-term antiretroviral therapy and opioid use disorder compound inflammaging—a low-grade chronic proinflammatory immune...
- The National Institute on Drug Abuse awarded Vanderbilt University Medical Center $825,492 on July 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a comparative analysis of buprenorphine dosing and clinical outcomes across pregnant and non-pregnant populations with opioid use disorder. The research addresses the gap between clinical evidence and practice in medication-assisted treatment during pregnancy. The study assesses national and state-level...
- The National Institute on Drug Abuse awarded The McLean Hospital Corporation $194,206 on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research identifying individual clinical and environmental predictors of buprenorphine response in patients with opioid use disorder. The project will harmonize data from five clinical trials on buprenorphine maintenance (N=1,439) to determine which patient characteristics predict treatment response at the individual...
- The National Institute on Drug Abuse awarded Wake Forest University Health Sciences $556,484 on June 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct cell-type-specific proteomic analysis of microglial protein dynamics in models of HIV and opioid use disorder comorbidity. The project employs a state-of-the-art proteomic strategy using a Cre-dependent mutant methionyl-tRNA synthetase system to label nascent proteins in microglia in vivo with the noncanonical...
- The National Institute on Drug Abuse awarded the University of California, San Diego $1,387,755 on March 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate mitochondrial oxidative phosphorylation dysregulation in HIV-associated neurocognitive disorder and opioid use disorder, with NAD+ treatment as a potential therapeutic strategy. The research establishes a three-dimensional human assembloid model composed of iPSC-derived neurons, astrocytes, microglia, and...
- The National Institute on Drug Abuse awarded Friends Research Institute, Inc. a $4.181 million Cooperative Agreement on September 15, 2025, to conduct a patient preference trial comparing extended-release injectable buprenorphine and sublingual buprenorphine-naloxone for individuals re-entering the community from jail, under the Drug Use and Addiction Research Programs (CFDA 93.279). The trial enrolls 500 adults with moderate to severe opioid use disorder soon-to-be-released from eight rural...
- The National Institute on Drug Abuse awarded Wayne State University $149,766 under the Drug Use and Addiction Research Programs (CFDA 93.279) on August 11, 2026, to conduct translational research examining perinatal exposure to concomitant opioid medications and antidepressants in a rodent model. The research investigates effects on the maternal brain, behavior, and offspring neurodevelopment, addressing a significant gap in understanding how medications for opioid use disorder (such as...